 |
18 Diseases |  |
32 Trials |
|
32 Trials |  |
839 News |  |
| «12345678910111213...1516» |
- || Clinical, Journal: Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases. (Pubmed Central) - Mar 7, 2021
Patients completed a protocol combining the pneumococcal vaccines PCV13 and PPV23...Patients on etanercept tended to achieve OPKA titers against a larger number of serotypes than the rest of patients on other biological therapies, while adalimumab was associated to a lower number of serotypes with OPKA titers...OPKA titers against serotype 3 which is one of the most prevalent, was obtained in 44% of patients, increasing up to 58% in those on etanercept. Hence, almost 50% of patients on biological therapy achieved functional antibodies after the administration of a complete pneumococcal vaccination protocol.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Review, Journal: Pneumococcal Choline-Binding Proteins Involved in Virulence as Vaccine Candidates. (Pubmed Central) - Mar 7, 2021
Currently, the available vaccines for the prevention of S. pneumoniae infections are the 23-valent pneumococcal polysaccharide-based vaccine (PPV-23) and the pneumococcal conjugate vaccines (PCV10 and PCV13)...In this review, we have focused the attention on different CBPs as vaccine candidates because they are involved in the pathogenesis process, confirming their immunogenicity and protection against pneumococcal infection. The review summarizes the major contribution of these proteins to virulence and reinforces the fact that antibodies elicited against many of them may block or interfere with their role in the infection process.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal, HEOR: Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations. (Pubmed Central) - Mar 3, 2021
Current pneumococcal vaccination recommendations for US older people are economically unfavorable compared to an alternative strategy omitting PCV13 in the immunocompetent. The alternative recommendation with an uptake improvement program may be economically reasonable in black population analyses and could be worth considering as a population-wide recommendation if mitigating racial disparities is a priority.
- Herceptin (trastuzumab) / Roche
[VIRTUAL] Hypofractionated radiation therapy after radical mastectomy: predictive factors of acute skin toxicity () - Mar 2, 2021 - Abstract #SGBCC2021SG_BCC_181;
No toxicity of grade ≥3 was detected in any patient and no case of treatment interruption occurred. Mean V105, V107 and V110 were respectively 8.6% (21.4 cc), 1.3% (3.3 cc) and 0.15% (0.2cc).
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Journal: Isolating polysaccharide IgG pneumococcal antibody responses by pre-adsorption of conjugate vaccine serotypes: A modified approach for the conjugate vaccine era. (Pubmed Central) - Mar 2, 2021
Mean V105, V107 and V110 were respectively 8.6% (21.4 cc), 1.3% (3.3 cc) and 0.15% (0.2cc). Pre-analytical modification to the conventional ELISA by removing the PCV-specific serotypes may differentiate true polysaccharide response from recall response induced by previous PCV vaccination.
- ||| Orencia (abatacept) / BMS
Trial completion, Trial primary completion date, Pneumococcal vaccines: VACINA: Vaccination Against Pneumococcal in Na (clinicaltrials.gov) - Mar 2, 2021
P=N/A, N=80, Completed, Sponsor: University Hospital, Montpellier
Pre-analytical modification to the conventional ELISA by removing the PCV-specific serotypes may differentiate true polysaccharide response from recall response induced by previous PCV vaccination. Active, not recruiting --> Completed | Trial primary completion date: Jan 2020 --> Jan 2021
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016. (Pubmed Central) - Feb 27, 2021
Active, not recruiting --> Completed | Trial primary completion date: Jan 2020 --> Jan 2021 Data does not support clinical benefits from pneumococcal vaccination (nor PCV13 neither PPsV23) against pneumonia among Catalonian adults in the current era of universal PCV's childhood immunisation.
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion, Trial completion date: IPS-BOOSTER: Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease (clinicaltrials.gov) - Feb 25, 2021
P4, N=300, Completed, Sponsor: Region Skane
Data does not support clinical benefits from pneumococcal vaccination (nor PCV13 neither PPsV23) against pneumonia among Catalonian adults in the current era of universal PCV's childhood immunisation. Active, not recruiting --> Completed | Trial completion date: Oct 2021 --> Dec 2020
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Retrospective data, Journal: Does pulmonary subspecialty referral from primary care affect the adherence to vaccination recommendations in COPD patients? (Pubmed Central) - Feb 20, 2021
Our study showed that referral to pulmonary clinic is associated with increased odds of receiving influenza (OR = 1.97, [95% CI 1.07, 3.65]) and pneumococcal vaccinations (PCV13 OR = 3.55, [1.47, 8.54]; PPSV23 OR = 4.92, [1.51, 16.02]). These data suggest that partnerships between primary care physicians and pulmonologists can potentially improve the vaccination rates for patients with COPD.
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Reimbursement, Journal, Medicare: Decline in Receipt of Vaccines by Medicare Beneficiaries During the COVID-19 Pandemic - United States, 2020. (Pubmed Central) - Feb 20, 2021
Weekly receipt of four vaccines (13-valent pneumococcal conjugate vaccine [PCV13], 23-valent pneumococcal polysaccharide vaccine [PPSV23], tetanus-diphtheria or tetanus-diphtheria-acellular pertussis vaccine [Td/Tdap], and recombinant zoster vaccine [RZV]) by Medicare beneficiaries aged ≥65 years during January 5-July 18, 2020, was compared with that during January 6-July 20, 2019, for the total study sample and by race and ethnicity...Vaccination declined sharply for all vaccines studied, overall and across all racial and ethnic groups. While the pandemic continues, vaccination providers should emphasize to patients the importance of continuing to receive routine vaccinations and provide reassurance by explaining the procedures in place to ensure patient safety (3).
- ||| Capvaxive (pneumococcal 21-valent conjugate vaccine) / Merck (MSD)
Enrollment open: Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002) (clinicaltrials.gov) - Feb 11, 2021
P1, N=100, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
While the pandemic continues, vaccination providers should emphasize to patients the importance of continuing to receive routine vaccinations and provide reassurance by explaining the procedures in place to ensure patient safety (3). Not yet recruiting --> Recruiting
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion, Phase classification, Trial completion date, Pneumococcal vaccines: Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines (clinicaltrials.gov) - Feb 10, 2021
P4, N=40, Completed, Sponsor: The Jackson Laboratory
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Phase classification: PN/A --> P4 | Trial completion date: Apr 2020 --> Aug 2020
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Review, Journal: Pneumococcal Pneumonia and Invasive Pneumococcal Disease in Those 65 and Older: Rates of Detection, Risk Factors, Vaccine Effectiveness, Hospitalisation and Mortality. (Pubmed Central) - Feb 10, 2021
Pneumococcal polysaccharide (PPV23) vaccination does not change nasal and pharyngeal carriage rates...To understand how seniors and especially older seniors acquire PP and IPD data are needed on pneumococcal disease and carriage rates in family members, carers and contacts. Nursing homes need reconfiguring into small units with air ventilation externally from all rooms to minimise respiratory disease transmission and dedicated staff for each unit to minimise transmision of infectious diseaases.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Obesity and STING1 genotype associate with 23-valent pneumococcal vaccination efficacy () - Feb 4, 2021 - Abstract #AFMRER2021AFMR_ER_32;
Sebastian M et al. Obesity and STING1 genotype associate with 23-valent pneumococcal vaccination efficacy.
- | Trial completion: Vaccinating Children After Chemotherapy (clinicaltrials.gov) - Feb 4, 2021
P4, N=156, Completed, Sponsor: Canadian Immunization Research Network
Obesity and STING1 genotype associate with 23-valent pneumococcal vaccination efficacy. Active, not recruiting --> Completed
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Impact of immunization with pneumococcal conjugated vaccines on the aplicability of the diagnostic criteria for specific pneumococcal antibody deficiency () - Feb 3, 2021 - Abstract #AAAAI2021AAAAI_864;
Antibody levels increased at least 2x for ≥50% of the serotypes in 59% of the PCV-experienced and 69% of the PCV-naïve patients after PPV23. Conclusions PCV immunization decreases the applicability of SAD diagnostic criteria in settings were a limited number of serotypes are tested. Efforts must be made to include as many PPV23 exclusive serotypes as possible in anti-pneumococcal antibody panels in order to obtain a relayable evaluation of the serologic response against PPV23 in PCV-experienced patients.
- ||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical: So interested to see results! I have a rtx patient six weeks post Covid who made no antibodies who has made antibodies to his prevnar/ppv23. He is getting vaccinated next week (hcw). He is 12 weeks post last Rtx. Planning on checking ab again post vaccination. Cd19 count 0. (Twitter) - Jan 30, 2021
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan. (Pubmed Central) - Jan 26, 2021
PPV23 is able to prevent IPD and 30-day fatality in adults 75 years of age and older due to a combination of direct effects from PPV23 and indirect effects from PCV13. It might confer higher protection against PPV23-serotype IPD before the introduction of PCV13 program in children.
- |||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Benlysta (belimumab) / GSK
Clinical: Don’t hold Benlysta for the COVID19 vaccine! Previous studies have shown that SLE pts on Benlysta (belimumab) still have good antibody response to vaccinations (including Prevnar14, PPSV23, flu and tetanus vaccines). @RheumNow https://t.co/4rFdcIKjkT (Twitter) - Jan 21, 2021
- ||| Capvaxive (pneumococcal 21-valent conjugate vaccine) / Merck (MSD)
Enrollment closed: A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001) (clinicaltrials.gov) - Jan 20, 2021
P1/2, N=590, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
It might confer higher protection against PPV23-serotype IPD before the introduction of PCV13 program in children. Recruiting --> Active, not recruiting
- || SP0202 / Sanofi, SK Bio
Trial primary completion date: Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years. (clinicaltrials.gov) - Jan 18, 2021
P2, N=750, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2021 --> Aug 2021
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Orencia (abatacept) / BMS
On abatacept one can mount responses to fluvax and PPV23 : much the same as age appropriate others (Twitter) - Jan 12, 2021
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] 13-valent pneumococcal conjugate vaccine (PCV13) versus 23-valent pneumococcal polysaccharide vaccine (PPSV23) versus both : A Triangular Debate (HALL - B) - Jan 11, 2021 - Abstract #NAPCON2020NAPCON_250;
- || methotrexate / Generic mfg.
Clinical, Journal: Immunogenicity of the currently recommended pneumococcal vaccination schedule in patients with inflammatory bowel disease. (Pubmed Central) - Jan 8, 2021
Although the sequential vaccination schedule of PCV13 followed by PPSV23 is safe, immunogenic and hence beneficial in the majority of IBD patients, those receiving immunosuppressive agents and especially those receiving combination therapy, have an impaired immune response compared to controls. Therefore, preferably, vaccinations should be administered before starting immunosuppressive therapy.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Early Impact of 13-valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease among Adults with and without Underlying Medical Conditions-United States. (Pubmed Central) - Jan 8, 2021
IPD incidence among U.S. adults declined after PCV13 introduction in children. Similar reductions in PCV13-type IPD in those with and without PCV13 indications suggest observed benefits are largely due to indirect effects from pediatric PCV13 use rather than direct use among adults.
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion, Enrollment change, Pneumococcal vaccines: Pneumococcal Vaccines in Patients With Asthma (clinicaltrials.gov) - Jan 7, 2021
P4, N=13, Completed, Sponsor: Mayo Clinic
Similar reductions in PCV13-type IPD in those with and without PCV13 indications suggest observed benefits are largely due to indirect effects from pediatric PCV13 use rather than direct use among adults. Recruiting --> Completed | N=50 --> 13
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Vaccination recommendation in newly diagnosed chronic lymphocytic leukaemia: a retrospective audit () - Jan 5, 2021 - Abstract #BSHI2020BSH-I_176;
The British Society of Haematology guidelines recommend that all patients with CLL should be offered seasonal influenza vaccination and pneumococcal vaccination (Prenvar 13‐conjugate vaccine and then Pneumovax 23‐polysaccharide vaccine)...A standard paragraph advising on vaccinations for all new patients with CLL. This will be added to clinic letters before sign off.3Re‐audit once awareness raised and proforma implemented in 6 months time
- | Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Journal: Drugs for COPD. (Pubmed Central) - Dec 30, 2020
This will be added to clinic letters before sign off.3Re‐audit once awareness raised and proforma implemented in 6 months time No abstract available
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Medication use evaluation of vaccination rates in patients with diabetes mellitus seen by internal medicine physicians at a rural primary care practice () - Dec 26, 2020 - Abstract #ASHP2020ASHP_4919;
A nationwide study in the United States reported vaccination rates of influenza, PPSV23, and hepatitis B in a patient population with diabetes to be 62%, 53%, and 17% respectively...Analysis will include the rate of vaccination for the group as a whole, each individual vaccine, and rates per provider. Subgroup analysis will also be performed on the various patient demographics.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Predictors of pneumococcal polysaccharide (PPSV23) vaccination in high-risk pediatric populations: a retrospective, cohort study () - Dec 26, 2020 - Abstract #ASHP2020ASHP_4187;
Subgroup analysis will also be performed on the various patient demographics. not applicable
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Improvement of appropriate pneumococcal vaccine use in a hospital setting () - Dec 26, 2020 - Abstract #ASHP2020ASHP_3360;
It will also lead to improved patient care, by reducing the risks of receiving a duplicate and unnecessary vaccinations. All policies regarding vaccine appropriateness in a hospital setting should be evaluated and improved continuously.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Identifying the gaps in patients’ asthma management plan at a family medicine clinic () - Dec 26, 2020 - Abstract #ASHP2020ASHP_3326;
Since a baseline was not obtained, it is unknown whether the implementation of the resident project improved asthma management. However, areas for improvement were discovered in education, immunizations and the creation of written action plans.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
[VIRTUAL] Impact of student pharmacist education on medical students’ immunization knowledge and perceptions of pharmacists in an interprofessional setting () - Dec 26, 2020 - Abstract #ASHP2020ASHP_2773;
This is evident by the improvement seen in medical students’ knowledge on vaccination in the elderly population following a pharmacy student presentation. In addition, the study showed that first year medical students included in this sample view pharmacists as valued individuals in an interprofessional setting.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Evaluation of pneumococcal conjugate vaccine 13-valent (PCV13) in adults () - Dec 26, 2020 - Abstract #ASHP2020ASHP_2684;
Updating the immunization navigator to reflect these recommendations, is estimated to save $132,430 over a 12-month period. Due to the low percentage of patients with indications being vaccinated with the current process, we recommended that the PCV13 standing order set for all inpatients be discontinued, while keeping PVC13 on formulary for neonates and adult patients per physician order.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Impact of pharmacist-led curbside influenza vaccination clinics in a family medicine center () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1484;
Similar to COVID-19, pneumonia is a respiratory illness. This may have driven the PPSV23 acceptance rate during study period for both groups.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Impact of a remote, telephonic population health introductory pharmacy practice experience on PDMP and immunization quality measures at a VA medical center () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1471;
Overall immunization appears to increase, even among those not contacted directly. In addition, PDMP checks performed by student pharmacists increase achievement of health-system goals and can identify potential medication related problems.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
[VIRTUAL] Evaluation of pneumococcal vaccine administration during pharmacist-led annual wellness visits (AWV) () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1392;
Pharmacists in outpatient primary care offices can play a key role in prevention by helping to improve access to pneumococcal vaccine administration and compliance with the CDC pneumococcal vaccine recommendations among patients. Further studies are needed to assess the overall impact of increasing vaccine rates due to pharmacist involvement.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Does pneumococcal vaccination reduce the risk of Alzheimer’s Disease in the US? () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1281;
This may be because we examined state-level rather than individual level. Further research is needed to determine whether pneumococcal vaccination might delay Alzheimer’s disease onset.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine, Zostavax (zoster vaccine live) / Merck (MSD)
[VIRTUAL] A Retrospective Review of Vaccination Rates in Older Adults () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1100;
Overall vaccination rates were lower than desired, especially for influenza in patients 65 years and older. Further data should be collected in order to further identify disparities and targeted interventions may be needed to improve vaccination rates.
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
[VIRTUAL] Clinical pharmacist interventions using a clinical dashboard to improve COPD management in a veteran population () - Dec 26, 2020 - Abstract #ASHP2020ASHP_734;
Data collected includes: COPD Assessment Test (CAT) scores, Modified Medical Research Council (mMRC) Dyspnea scores, GOLD group classification, smoking history and tobacco cessation medications, and history including asthma, vaccinations (influenza, PCV-13, PPSV-23), COPD medications and COPD exacerbations. Type and number of CPS interventions will be analyzed, including medication changes, education and smoking cessation therapy provided, vaccines ordered or recommended, and referrals made.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study. (Pubmed Central) - Dec 22, 2020
In the setting of an established national childhood PCV13 vaccination programme, PPV23 vaccination of clinical at-risk patient groups and adults aged ≥65 years provided moderate long-term protection against hospitalisation with PPV23 serotype pneumonia. These findings suggest that PPV23 vaccination may continue to have an important role in adult pneumococcal vaccine policy, including the possibility of revaccination of older adults.
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Journal: Relationship between asthma status and antibody response pattern to 23-valent pneumococcal vaccination. (Pubmed Central) - Dec 19, 2020
We recommend the consideration of asthma status when interpreting vaccine response for immune competence workup through larger studies. Further studies are warranted to replicate these findings.
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Journal: Dosimetric comparison of short and full arc in spinal PTV in volumetric-modulated arc therapy-based craniospinal irradiation. (Pubmed Central) - Dec 19, 2020
However, the VMAT_PA plan exhibited a lower D compared to VMAT_FA plans (0.007 ≤ p < 0.05) in the 1 to 5 Gy range. Nevertheless, partial arc plans could not offer a statistically significant dose reduction for delineated organs compared to full arc plans, except for bilateral kidneys.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical, Journal: The estimated impact of the 5-year national vaccination program on the trend of 23-valent pneumococcal polysaccharide vaccine vaccination rates in the elderly in Japan, 2009-2018. (Pubmed Central) - Dec 18, 2020
Stepwise regression analysis revealed that the annual PPV23 vaccination rate significantly increased after 2014 (from 2 to 5% prior to 2014, to 10-11% after 2014), and remained steady for 2014-2018. Our findings suggest that the 5-year national routine vaccination subsidy program was successful in achieving a steady and higher vaccination rate of PPV23 in Japan.
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Journal: Diffuse cutaneous reaction following PPV-23 pneumococcal vaccine: an immunisation-associated hypersensitivity vasculitis. (Pubmed Central) - Dec 18, 2020
Our findings suggest that the 5-year national routine vaccination subsidy program was successful in achieving a steady and higher vaccination rate of PPV23 in Japan. No abstract available
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Retrospective data, Review, Journal: The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis. (Pubmed Central) - Dec 18, 2020
Polysaccharide pneumococcal vaccination decreased the risk for some adverse cardiovascular events, specifically acute MI in the vaccinated population, particularly for those individuals aged ≥65 years. It would be highly beneficial to vaccinate the population who is at greater risk of cardiovascular diseases.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Biomarker, Clinical, Retrospective data, Journal: Characterization of adult patients with IgG subclass deficiency and subnormal IgG2. (Pubmed Central) - Dec 16, 2020
It would be highly beneficial to vaccinate the population who is at greater risk of cardiovascular diseases. Characteristics of adults with IgGSD with subnormal IgG2 include female predominance, other immunologic abnormalities, subnormal IgG3 and/or IgG1, lack of HLA-A and -B association, and suboptimal PPSV23 response.
- ||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical: Thanks for the input. Not asked correctly as more interested in studies to determine formation of antibodies versus safety. Have had several discussions with sMM pts with immuneparesis that have difficulty with Abs to Prevnar and PPV23 so wondering if this vaccine would work? (Twitter) - Dec 13, 2020
- | Capvaxive (pneumococcal 21-valent conjugate vaccine) / Merck (MSD)
New P1 trial: Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002) (clinicaltrials.gov) - Dec 11, 2020
P1, N=100, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Retrospective data, Review, Journal: Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis. (Pubmed Central) - Dec 10, 2020
Compared to PPSV alone, a combination of PCV/PPSV yielded higher SCRs (OR 2.24 95% CI 1.41- 3.58), whereas we did not observe a significant difference in SCR between PCV and PPSV23 alone...We recommend reassessment of this strategy once higher-valent PCVs become available. HMGG is funded by a public research grant of ZonMw (project number 522004005).